2012-209 – Mayo Clinic researchers have developed methods and materials for treating cancer through the use of antigen combinations. For example, Vesicular Stomatitis Virus (VSV) vectors designed to express a GNAQ antigen, a TYRP1 anti-gen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal. In some cases, VSV vectors designed to express... Read More
2009-139 – Technology Description Mayo Clinic researchers have exploited normal blood-brain barrier (BBB) transport mechanisms utilized by apolipoproteins to deliver agents across the BBB and have designed peptides incorporating apolipoprotein LDL receptor binding sequences. These peptides contain additional amino acid sequences to facilitate the binding and delivery of various biological and chemical... Read More
2001-153 – Circulating smooth muscle progenitor cells (SPC) in humans.
1999-061 – This is a cell therapy delivery system which allows efficient and long term vascular delivery.